Long-term miglustat therapy in children with niemann-pick disease type C

Marc C. Patterson, Darleen Vecchio, Elizabeth Jacklin, Larry Abel, Harbajan Chadha-Boreham, Cecile Luzy, Ruben Giorgino, James E. Wraith

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Niemann-Pick disease type C is a rare, genetic disease associated with impaired intracellular lipid trafficking and progressive neurological symptoms. Miglustat slowed disease progression in a 12-month randomized trial in juveniles and adults with Niemann-Pick disease type C, and in a parallel, noncontrolled study in affected children. Here, the authors report the open-label extension to the pediatric study. Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase. Efficacy assessments included horizontal saccadic eye movement, swallowing, and ambulation. Ten children completed 24 months treatment. Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months. Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%). Miglustat stabilized neurological disease progression in pediatric patients with Niemann-Pick disease type C, with comparable safety and tolerability to that observed in adults and juveniles.

Original languageEnglish (US)
Pages (from-to)300-305
Number of pages6
JournalJournal of Child Neurology
Volume25
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Type C Niemann-Pick Disease
Disease Progression
Saccades
Deglutition
Walking
Pediatrics
Inborn Genetic Diseases
Body Surface Area
Rare Diseases
Therapeutics
Lipids
Safety
miglustat

Keywords

  • Efficacy
  • Miglustat
  • Niemann-Pick disease type C
  • Safety

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Patterson, M. C., Vecchio, D., Jacklin, E., Abel, L., Chadha-Boreham, H., Luzy, C., ... Wraith, J. E. (2010). Long-term miglustat therapy in children with niemann-pick disease type C. Journal of Child Neurology, 25(3), 300-305. https://doi.org/10.1177/0883073809344222

Long-term miglustat therapy in children with niemann-pick disease type C. / Patterson, Marc C.; Vecchio, Darleen; Jacklin, Elizabeth; Abel, Larry; Chadha-Boreham, Harbajan; Luzy, Cecile; Giorgino, Ruben; Wraith, James E.

In: Journal of Child Neurology, Vol. 25, No. 3, 03.2010, p. 300-305.

Research output: Contribution to journalArticle

Patterson, MC, Vecchio, D, Jacklin, E, Abel, L, Chadha-Boreham, H, Luzy, C, Giorgino, R & Wraith, JE 2010, 'Long-term miglustat therapy in children with niemann-pick disease type C', Journal of Child Neurology, vol. 25, no. 3, pp. 300-305. https://doi.org/10.1177/0883073809344222
Patterson MC, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C et al. Long-term miglustat therapy in children with niemann-pick disease type C. Journal of Child Neurology. 2010 Mar;25(3):300-305. https://doi.org/10.1177/0883073809344222
Patterson, Marc C. ; Vecchio, Darleen ; Jacklin, Elizabeth ; Abel, Larry ; Chadha-Boreham, Harbajan ; Luzy, Cecile ; Giorgino, Ruben ; Wraith, James E. / Long-term miglustat therapy in children with niemann-pick disease type C. In: Journal of Child Neurology. 2010 ; Vol. 25, No. 3. pp. 300-305.
@article{fc30843cc5aa4cea8d846dc7f28eb347,
title = "Long-term miglustat therapy in children with niemann-pick disease type C",
abstract = "Niemann-Pick disease type C is a rare, genetic disease associated with impaired intracellular lipid trafficking and progressive neurological symptoms. Miglustat slowed disease progression in a 12-month randomized trial in juveniles and adults with Niemann-Pick disease type C, and in a parallel, noncontrolled study in affected children. Here, the authors report the open-label extension to the pediatric study. Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase. Efficacy assessments included horizontal saccadic eye movement, swallowing, and ambulation. Ten children completed 24 months treatment. Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months. Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80{\%}). Miglustat stabilized neurological disease progression in pediatric patients with Niemann-Pick disease type C, with comparable safety and tolerability to that observed in adults and juveniles.",
keywords = "Efficacy, Miglustat, Niemann-Pick disease type C, Safety",
author = "Patterson, {Marc C.} and Darleen Vecchio and Elizabeth Jacklin and Larry Abel and Harbajan Chadha-Boreham and Cecile Luzy and Ruben Giorgino and Wraith, {James E.}",
year = "2010",
month = "3",
doi = "10.1177/0883073809344222",
language = "English (US)",
volume = "25",
pages = "300--305",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term miglustat therapy in children with niemann-pick disease type C

AU - Patterson, Marc C.

AU - Vecchio, Darleen

AU - Jacklin, Elizabeth

AU - Abel, Larry

AU - Chadha-Boreham, Harbajan

AU - Luzy, Cecile

AU - Giorgino, Ruben

AU - Wraith, James E.

PY - 2010/3

Y1 - 2010/3

N2 - Niemann-Pick disease type C is a rare, genetic disease associated with impaired intracellular lipid trafficking and progressive neurological symptoms. Miglustat slowed disease progression in a 12-month randomized trial in juveniles and adults with Niemann-Pick disease type C, and in a parallel, noncontrolled study in affected children. Here, the authors report the open-label extension to the pediatric study. Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase. Efficacy assessments included horizontal saccadic eye movement, swallowing, and ambulation. Ten children completed 24 months treatment. Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months. Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%). Miglustat stabilized neurological disease progression in pediatric patients with Niemann-Pick disease type C, with comparable safety and tolerability to that observed in adults and juveniles.

AB - Niemann-Pick disease type C is a rare, genetic disease associated with impaired intracellular lipid trafficking and progressive neurological symptoms. Miglustat slowed disease progression in a 12-month randomized trial in juveniles and adults with Niemann-Pick disease type C, and in a parallel, noncontrolled study in affected children. Here, the authors report the open-label extension to the pediatric study. Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase. Efficacy assessments included horizontal saccadic eye movement, swallowing, and ambulation. Ten children completed 24 months treatment. Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months. Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%). Miglustat stabilized neurological disease progression in pediatric patients with Niemann-Pick disease type C, with comparable safety and tolerability to that observed in adults and juveniles.

KW - Efficacy

KW - Miglustat

KW - Niemann-Pick disease type C

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=77649249576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649249576&partnerID=8YFLogxK

U2 - 10.1177/0883073809344222

DO - 10.1177/0883073809344222

M3 - Article

C2 - 19822772

AN - SCOPUS:77649249576

VL - 25

SP - 300

EP - 305

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 3

ER -